The ARAI Autoinjector represents a next-generation solution for administering emergency treatments for life-threatening conditions. It is uniquely designed to be simple to use, rugged, and to support multiple configurations within the same form factor. Key features include single-hand operation, one-step activation and multi-sensory feedback to minimize user errors. The autoinjector utilizes a glass-free, high-barrier, flexible polymer film primary drug container for improved drug stability. The robust ARAI platform is engineered for 99.999% reliability under the toughest environmental conditions.

PenPal is a new class of autoinjectors that brings reliability, user-friendliness, and versatility to routine at-home injections. Building on the robust foundation of ARAI, PenPal is engineered to meet 99.999% reliability rating. Its patented user centric design sets a new standard in ease of use and user comfort. Powered by pressurized gas, this versatile platform is adept at handling both small molecule drugs and biologics in conventional prefilled syringe and cartridge primary drug containers. PenPal also features multi-sensory feedback, significantly reducing the chances of user error.

ARCH-Vial utilizes advanced high-barrier polymer films to surpass the performance and functionality of traditional glass packaging. This innovative solution addresses the potential issues of interactions between biologics and glass containers, elevating aseptic barriers, and offering an improved option for drugs requiring reconstitution at the point of use. Furthermore, it lays the groundwork for combination products that are more efficient and user-friendly.

Aktiv Pharma Group is a vertically integrated company that specializes in the development and manufacturing of drug-device combination products, offering a full range of services from design to sterile fill-finish. With a skilled 22-person team, it addresses all aspects of product creation, from device development to quality and cleanroom operations, aiming to streamline the journey from innovation to clinical production.